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Oral squamous cell carcinomaThe excessive use of areca nut and/or tobacco may induce the production of free radicals and reactive oxygen
species, which affect the lipid contents of the cell membrane and are possibly involved in tumorigenic
processes in the oral cavity. The aimof this studywas to investigate the therapeutic efﬁcacy of fenoﬁbrate (0.1%
or 0.3%, w/w), a ligand of the peroxisome proliferator-activated receptor alpha (PPARα), in a 4-nitroquinoline
1-oxide (4-NQO)/arecoline-induced oral cancer mouse model. The carcinogen, 4-NQO/arecoline, was
administrated to C57BL/6JNarl mice for 8 weeks followed by fenoﬁbrate treatment for 12 or 20 weeks. After
28 weeks, changes in serum lipids, themultiplicity of tumor lesions, and tumor sizeswere determined together
with changes in the immunohistochemical expressions of PPARα, acetyl-coenzyme A carboxylase (ACC), the
epidermal growth factor receptor (EGFR), and cyclooxygenase-2 (COX2). The results showed that when
compared to the 4-NQO/arecoline only group, 0.3% fenoﬁbrate treatment increased serum total cholesterol,
low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels. 0.3%
fenoﬁbrate treatment suppressed the incidence rate of tongue lesions, reduced the multiplicity of squamous
cell carcinoma (SCC), decreased the tumor size, and increased the immunoreactivity of EGFR and COX2 in oral
dysplasia but decreased EGFR and COX2 expressions in SCC. These ﬁndings indicated that fenoﬁbrate reduced
the tumor incidence rate and suppressed the tumor progression into SCC and that these molecular events
might be linked to the EGFR and COX2 regulatory pathways. We suggest that fenoﬁbrate provides a new
strategy for preventing oral tumor progression.lase; BQ, betel quid; COX2,
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Smoking, betel quid (BQ) chewing, and the consumption of alcohol
and coffee are common habits related to the incidence of oral cancer
[1]. Most patients with oral cancer are not diagnosed until theadvanced stages of the disease and often fail to respond to available
therapies. Therefore, the 5-year survival rate of oral cancer patients is
relatively low when compared to other types of cancer [2]. Thus,
understanding whether precancerous lesions and their progression to
cancer can be prevented will aid in the development of novel
molecular strategies for oral cancer prevention and treatment.
The excessive use of areca nut and/or tobacco induces the
production of free radicals and reactive oxygen species, which are
responsible for the high rate of oxidation/peroxidation of polyunsat-
urated fatty acids [3]. Lipid peroxidation affects essential constituents
of the cell membrane andmay be involved in tumorigenic processes in
the oral cavity [4,5]. Lipids are the major cell membrane components
essential for various biological functions including cell growth and the
division of normal and malignant tissues. An inverse association was
found between a lower plasma lipid proﬁle and head and neck
malignancies and an oral precancerous condition [6,7]. The lower
levels of plasma lipids in oral cancer patients might be due to their
increased utilization by neoplastic cells for biosynthesis of new
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developing a new therapeutic strategy for the treatment of oral
cancer. This hypolipidemic strategy would be beneﬁcial in preventing
the development of oral tumorigenesis.
The peroxisome proliferator-activated receptor alpha (PPARα), a
member of the nuclear receptor superfamily of ligand-activated
transcription factors, is a key regulator of lipolysis, triglyceride-rich
lipoprotein metabolism, and inﬂammatory/vascular pathways [8–11].
Fenoﬁbrate, a ligand of PPARα, is a widely used hypolipidemic drug
with anti-inﬂammatory and anti-atherosclerotic effects in the vessel
wall [8,10]. Fenoﬁbrate exerts a wide spectrum of lipid-modifying
actions that inﬂuence atherogenic dyslipidemia, such as a reduction in
levels of triglycerides, very low-density lipoproteins (VLDL), VLDL
remnants, intermediate-density lipoproteins, an increase in plasma
levels of high-density lipoprotein (HDL) cholesterol, and a decrease in
the proportion of small, dense low-density lipoprotein (LDL) particles
in the LDL density proﬁle [12,13].
To explore whether oral tumorigenesis can be prevented by
fenoﬁbrate, animal models that faithfully simulate the human oral
cancer condition are critical. 4-nitroquinoline 1-oxide (4-NQO) is one
of the chemical carcinogens used for inducing oral carcinogenesis and
served as a surrogate for tobacco exposure [14]. Arecoline, the major
alkaloid in areca nut extracts and BQ, promoted 4-NQO carcinogenesis
in mice [15]. Our previous studies showed that 4-NQO plus arecoline-
induced oral lesions manifested as epithelial hyperplasia, dysplasia,
and invasive squamous cell carcinoma (SCC), which mimicked the
pathogenesis, environment, and subsequent molecular events in SCC
patients in Southeast Asia and Taiwan [15–17]. In this model, the
tongue tumor incidence rate was 100% in mice treated concomitantly
with 200 μg/ml 4-NQO and 500 μg/ml arecoline for 8 weeks, and
many tongue lesions evolved spontaneously into highly malignant
invasive SCC over the following 20 weeks. Therefore, the present
study was aimed to investigate the therapeutic efﬁcacy of fenoﬁbrate
in a 4-NQO/arecoline-induced oral tumorigenesis mouse model.
Changes in plasma lipids and tumor size were determined along
with variations in the immunohistochemical expressions of PPARα,
fatty acid synthase (FAS), acetyl-coenzyme A carboxylase (ACC),
epidermal growth factor receptor (EGFR), and cyclooxygenase-2
(COX2), which are involved in lipid metabolism and inﬂammatory/
tumor progression pathways [8,10,16,18].
2. Material and methods
2.1. Administration of 4-NQO and arecoline
Sixty 6-week-old male C57BL/6JNarl mice were purchased from
the National Laboratory Animal Center. The mice were handled in
accordance with the Animal Care and Use Guidelines of the China
Medical University, and the study protocol was approved by the
Institutional Animal Care Use Committee. Mice were randomized intoTable 1
Body weights in each group during the 28-week treatment.
Group treatment (10 mice in each group)
Group
number
4-NQO/arecoline-induced
period (weeks)
Dose of fenoﬁbrate
(g/100 g diet)
Period of fen
treatment (w
1 0 0 0
2 8 0 0
3 8 0.1 12
4 8 0.3 12
5 8 0.1 20
6 8 0.3 20
a Signiﬁcantly different from group 1 by One way ANOVA (pb0.005).
b Signiﬁcantly different from group 2 by One way ANOVA (pb0.001).
c Signiﬁcantly different from group 3 by One way ANOVA (pb0.005).
d Signiﬁcantly different from group 4 by One way ANOVA (pb0.05).one of six groups (Table 1). The experiments were carried out under
controlled conditions with a 12-h light/dark cycle. Mice were fed with
standard mouse chow (Prolab® RMH 2500 PMI Nutrition Interna-
tional, LLC, MO, USA). The carcinogens, 200 μg/ml 4-NQO (Sigma-
Aldrich, St. Louis, MO, USA) and 500 μg/ml arecoline hydrobromide
(Fluka, Buchs, China), were dissolved in the drinking water; the water
was replaced once a week. Ten mice per group were allowed to access
the drinking water and chow diet ad libitum during the treatment. All
mice were weighed every 4 weeks.
2.2. Fenoﬁbrate treatment
For the analysis of the effects of fenoﬁbrate on tumor development,
mice were exposed to 4-NQO/arecoline for 8 weeks and then
randomly divided into six treatment groups for the following
20 weeks, as shown in Table 1. Mice received fenoﬁbrate orally either
at a low dose of 0.1% diet/mouse/day (about 200 mg/kg body weight/
day) or at a high dose of 0.3% diet/mouse/day (about 500 mg/kg body
weight/day). Chow diet was ground into powder, and the powdered
diet was used as a basal diet during the experiment. The experimental
diet was prepared by mixing fenoﬁbrate (0.1% or 0.3%, w/w) with the
powdered diet. All mice were monitored, and diets were replaced
daily. To maintain the diet stability, all diets were stored at 4 °C before
use. Precancerous and cancerous lesions of the tongue were
diagnosed and photographed bi-weekly. According to our previous
study [15,16], a therapeutic window between week 14 and week 20
was observed in this mouse model. In this study protocol, adminis-
tration of fenoﬁbrate from week 9 to week 20 (a total 12 weeks) was
designed to explore whether a lowering of serum lipids would affect
preneoplastic lesion formation. In addition, administration of fenoﬁ-
brate from week 9 to week 28 (a total 20 weeks) was intended to
investigate the effects of long-term fenoﬁbrate treatment on
tumorigenesis. At the end of 28 weeks, all mice were sacriﬁced after
a 12-h overnight fast for blood analysis. The tongues were then
excised and ﬁxed in 10% formaldehyde for pathological and
immunohistochemical analysis.
2.3. Serum lipids analysis
At the end of 28 weeks, blood samples were obtained from each
mouse after a 12-h overnight fast. The serum concentrations of the total
cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and
triglyceride were measured by a Roche/Hitachi COBAS MIRA PLUS
analyzer.
2.4. Tongue lesion and pathological examination
Parafﬁn-embedded tongue specimens were stained with hema-
toxylin and eosin for histopathological examination. The lesions
observed were classiﬁed as epithelial hyperplasia, dysplasia, orBody weight (g)
oﬁbrate
eeks)
0 week 8 weeks 20 weeks 28 weeks
23.2±1.7 28.7±2.1 33.3±3.0 33.6±3.3
22.8±1.6 25.8±1.7a 29.4±2.8a 25.7±4.1a
22.6±1.1 25.8±1.2a 27.6±1.9a 27.3±3.3a
22.5±1.2 24.8±2.0a 23.5±3.1a,b,c 26.2±4.2a
22.2±1.7 24.9±1.9a 27.0±1.9a,d 25.5±3.2a
22.9±1.3 25.3±1.1a 24.4±1.2a,b 22.8±1.5a
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previously described [15]. The multiplicity from all tumor lesions in
each tongue was evaluated as previously described [19]. Tongue
lesions attained from 4-NQO/arecoline-induced mice after the 28-
week time point were more widespread, thus the number of every
macroscopic tumor lesions was counted. The tumor sizes of visible
lesions in each tongue were measured individually in width (mm)
and only the largest lesion is presented in statistics (Fig. 1C). For
example, in a case with four lesions with the widths of 3 mm, b1 mm,
1.5 mm, and 1 mm, the tumor size in this animal was recorded as
3 mm as shown in Fig. 1B.Fig. 1. Incidence of tongue lesions and tumor size in each group after a 28-week
treatment. Ten mice in each group were examined. (A) The incidence of tongue lesions
was presented as the percentage of mice exhibiting tongue lesions after 28 weeks.
Lesions included hyperplasia, dysplasia, and invasive squamous cell carcinoma. (B) The
tongue lesions in one representative mouse are shown by arrows. The tumor sizes were
measured as 3 mm, b1 mm, 1.5 mm, and 1 mm, respectively. (C) The tumor sizes in
each group are presented as indicated. Group treatments are described as in Table 1.
Mice treated concomitantly with fenoﬁbrate (0.3%, w/w) and 4-NQO/arecoline (group
6) had a signiﬁcant decrease in the incidence of tongue lesions (pb0.05, 1A) and tumor
size (pb0.05, 1 C) when compared with the 4-NQO/arecoline treated mice (group 2)
using Fisher's exact test.2.5. Immunohistochemical analysis
Four primary antibodies from Abcam, Cambridge, UK were used at
the following concentrations: PPARα (ab2779) mouse monoclonal
antibody, 1:200; FAS (ab22759) rabbit polyclonal antibody, 1:100;
ACC (ab45174) rabbit monoclonal antibody, 1:30; and EGFR (ab2430)
rabbit polyclonal antibody, 1:50. A rabbit monoclonal antibody
against COX-2 (Cat. no. 4212-1, Epitomics, California, USA) was used
at a 1:100 dilution. During immunostaining, samples were ﬁrst
treated with a target retrieval solution (Dako, Denmark) and then
incubated with the diluted primary antibody for 60 min at 25 °C. Next,
samples were thoroughly washed three times with PBS, treated with
diaminobenzidine as the chromogen, and incubated with EnVision-
Plus (Dako, Carpinteria, CA, USA) for 30 min. The skeletal muscle
derived from murine tongue tissue was used as an internal positive
control for the staining quality of these ﬁve antibodies. The staining
intensities were graded as negative (−), weak positive in less than
10% of the area (+/−), weak positive (1+), moderate positive (2+),
and strong positive (3+) [19]; the staining intensities were scored as
0, 1, 2, 3, and 4, respectively. All lesions in each tongue were scored.
For example, in a case with two lesions, the results of histopatholog-
ical diagnosis were hyperplasia and SCC. The staining intensities of
weak positive staining in hyperplasia and of moderate positive
staining in SCC would be assigned a score of 2 and 3, respectively.
2.6. Statistical analysis
All data were analyzed using SPSS 15.0 for Windows. Signiﬁcant
differences in body weight, total cholesterol, triglyceride, LDL-C, and
HDL-C between groups were analyzed using the one way analysis of
variance (ANOVA) followed by multiple comparison tests. Statistical
analyses of the tumor size and incidence of tongue lesions were
performed using Fisher's exact probability test. Immunostaining
intensities, which included PPARα, FAS, ACC, EGFR, and COX2, were
compared using the one way ANOVA. A p-value of less than 0.05 was
considered statistically signiﬁcant. All data are shown as mean±S.D.
3. Results
3.1. Body weight changes during the 28-week treatment
Mice administered 4-NQO/arecoline and fenoﬁbrate did not
display any clinical signs of poor health or a low survival rate. There
were no signiﬁcant differences in the average food intake of the 4-
NQO/arecoline groups fed with or without fenoﬁbrate (data not
shown). The body weight changes in each group over the 28-week
time course are shown in Table 1. At the end of 8 weeks, the body
weight was signiﬁcantly lower in mice fed with 4-NQO/arecoline than
in mice fed with tap water (group 1; pb0.005, Table 1). After week 8,
4-NQO/arecoline administration was discontinued, and mice were
treated with high (0.3%) or low (0.1%) doses of fenoﬁbrate. At the end
of 20 weeks, the body weight was lower in mice fed with 0.3%
fenoﬁbrate (group 4, pb0.001; group 6, pb0.001) than that in mice
fed the basal diet (Group 2). When fenoﬁbrate administration was
continued until 28 weeks, the average bodyweight slightly decreased,
but no signiﬁcant differencewas found between groups 5 and 6. At the
end of 28 weeks, the body weight was the highest in group 1.
3.2. Effects of fenoﬁbrate on serum lipid levels
After the 28-week treatment, mice treated with 4-NQO/arecoline
(group 2) showed a signiﬁcant increase in serum LDL-C when
compared with control mice (group 1) (pb0.05, Table 2). Adminis-
tration of 0.3% fenoﬁbrate to 4-NQO/arecoline-induced mice for
20 weeks (group 6) showed signiﬁcant increases in serum total
cholesterol (pb0.001), LDL-C (pb0.001), and HDL-C (pb0.001) levels
Table 2
Serum lipids concentration in each group after 28 weeks.
Group treatment (10 mice in each group) Serum lipids
Group number 4-NQO/arecoline-induced
period (weeks)
Dose of fenoﬁbrate
(g/100 g diet)
Period of fenoﬁbrate
treatment (weeks)
Total cholesterol
(mg/dl)
LDL-C
(mg/dl)
HDL-C
(mg/dl)
Triglyceride
(mg/dl)
1 0 0 0 65.2±5.6 6.9±1.2a 46.9±3.6 41.4±4.5
2 8 0 0 64.7±8.5 12.8±5.6 43.8±4.9 48.6±11.9
3 8 0.1 12 65.9±9.4 9.3±2.6 45.7±3.7 33.5±15.6
4 8 0.3 12 68.5±8.4 11.4±2.5 50.0±5.7a 41.7±20.1
5 8 0.1 20 70.4±3.8 14.0±2.3 51.0±2.0a 57.3±5.5c
6 8 0.3 20 92.7±5.1b,e 24.4±5.7 b,c,e 65.9±3.8b,c,e 61.5±4.2 d
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
a Signiﬁcantly different from group 2 by One way ANOVA (pb0.05).
b Signiﬁcantly different from group 2 by One way ANOVA (pb0.001).
c Signiﬁcantly different from group 3 by One way ANOVA (c, pb0.005).
d Signiﬁcantly different from group 4 by One way ANOVA (pb0.01).
e Signiﬁcantly different from group 4 by One way ANOVA (pb0.001).
Table 3
Multiplicity of tongue lesions in mice after 28-week treatment.
Group number 1 2 6
Group treatment
4-NQO/arecoline-induced period (weeks) 0 8 8
Dose of fenoﬁbrate (g/100 g diet) 0 0 0.3
Period of fenoﬁbrate treatment (weeks) 0 0 20
No. of mice 10 10 10
Multiplicity (no. of tongue lesions/mouse, mean±SD)
Hyperplasia 0 1.00±0.00 1.00±0.00
Mild dysplasia 0 0.40±0.52 0.20±0.42
Moderate dysplasia 0 0.40±0.52 0.60±0.52
Severe dysplasia 0 0.40±0.52 0.30±0.48
SCC 0 0.80±0.42 0.30±0.48a
a Signiﬁcantly different from group 2 by One way ANOVA (pb0.05).
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fenoﬁbrate treatment for 12 weeks (group 4) did not display the
above hypercholesterolemic effects of the 20-week fenoﬁbrate
treatment. In addition, no signiﬁcant differences in triglyceride levels
were observed between the 4-NQO/arecoline only group and the
fenoﬁbrate-treated groups (Table 2). When both 0.1% and 0.3%
fenoﬁbrate administration in groups 5 and 6 was extended from
12 weeks to 20 weeks, the serum triglyceride levels signiﬁcantly
increased (group 5 vs. group 3, pb0.005; group 6 vs. group 4, pb0.01).
3.3. Effects of fenoﬁbrate on tumor incidence and tumor formation
To carefully characterize the development of tumors in this model,
lesions of the tongue were examined and photographed bi-weekly. As
found in our previous report [15], no tongue lesion was found in the 4-
NQO/arecoline-induced groups at week 8. However, the incidence of
tongue lesions increased spontaneously over the following 20 weeks.
After 28 weeks, the incidence rate of tongue lesions in the 0.3%
fenoﬁbrate-treated mice (group 6) was lower than that in the 4-NQO/
arecolineonly group(pb0.05, Fig. 1A).We compared the incidence rates
between different fenoﬁbrate-treated durations. The results indicated
that the administration of 0.3% fenoﬁbrate did not show a signiﬁcant
difference (p=0.35) in the incidence rates between the 12-week (80%,
group 4) and the 20-week (50%, group 6) treatment groups (Fig. 1A).
Since all mice exposed to 4-NQO/arecoline developed one or more
lesions, the largest lesion per mouse from each group was compared
at the end of 28 weeks. The administration of 0.3% fenoﬁbrate (group
6) signiﬁcantly reduced the tumor size compared with tumors in the
mice treated with 4-NQO/arecoline only (group 2, pb0.05, Fig. 1C)
after the 28-week observation. In group 2, we found three mice with a
small lesion (b2 mm), three mice with a medium lesion (2–4 mm),
and four mice with a large lesion (N4 mm). As for the fenoﬁbrate
treatment (group 6), ﬁve mice were lesion free, four mice had small
lesions, and one mouse with a medium lesion. In addition, no
signiﬁcant difference in tumor size was found between group 4, which
was treated with 0.3% fenoﬁbrate for 12 weeks, and group 2
(p=0.071) or between groups 4 and 6 (p=0.106). These results
indicated that 0.3% fenoﬁbrate suppressed the tumor incidence and
formation after continuing administration for 20 weeks.
3.4. Multiplicity of tongue lesions in mice treated with fenoﬁbrate
Based on group 6 having the lowest incidence of tongue tumors
after 0.3% fenoﬁbrate treatment, we conducted a detailed histological
analysis of the tongue lesions among groups 1, 2, and 6. The
multiplicity of the tongue was evaluated from all lesions in each
tongue because tongue lesions obtained from 4-NQO/arecoline mice
after the 28-week time point were more widespread. The tongue
lesions were classiﬁed into ﬁve categories of hyperplasia, milddysplasia, moderate dysplasia, severe dysplasia, and SCC. The
multiplicity of SCC in group 6 was signiﬁcantly lower than that in
group 2 (pb0.05, Table 3). This ﬁnding indicated that fenoﬁbrate
suppressed tumor progression into SCC.
3.5. Expressions of PPARα, ACC, EGFR, FAS, and COX2 during the
histological progression of oral tumorigenesis in fenoﬁbrate-treated mice
Immunohistochemical staining of PPARα, ACC, EGFR, and COX2
was examined from all lesions in each tongue in groups 2 and 6. The
results of the immunohistochemical expressions among histological
grades in the tongue lesions are shown in Fig. 2. The staining intensity
of PPARα, ACC, EGFR, and COX2 in normal epithelium, squamous
hyperplasia, dysplasia, and SCC was increased through the progres-
sion of the lesions from hyperplasia to SCC. PPARα, a ligand-activated
transcription factor, which is a key regulator of lipid metabolism and
inﬂammatory/vascular pathways, was expressed in the nucleus
(Fig. 2A). Expression of ACC, a rate-limiting enzyme that catalyzes
the formation of malonyl CoA (precursor for long chain fatty acyl CoA)
from acetyl CoA, was found in the cytoplasm of immuno-positive cells
(Fig. 2B). Expression of EGFR, a prototype member of the type 1
receptor tyrosine kinases, was found in the cell membrane (Fig. 2C).
The EGFR and its downstream effectors signal diverse cellular
functions, including cell proliferation, differentiation, motility, sur-
vival, and tissue development [16]. Expression of COX2 was found in
the cytoplasm (Fig. 2D). The elevated levels of COX2 expression are
involved in the possible contribution of proinﬂammatory pathways
[18]. A diffuse immunoreactivity of COX2was present in the epithelial
dysplasia and SCC (Fig. 2D). Also, minimal lymphocytic inﬁltration
was noted (Supplementary Fig. 1).
In addition, the results of the semi-quantitative scoring of the
immunoreactivity in the tongue lesions of group 2 (4-NQO/arecoline
treatment only) and group 6 (0.3% fenoﬁbrate treatment) are shown
in Fig. 3. Administration of 0.3% fenoﬁbrate signiﬁcantly increased the
Fig. 2. Immunohistochemical staining of PPARα, ACC, EGFR, and COX2 in the 4-NQO/arecoline mouse model of oral cancer. Tissue sections containing areas of normal, hyperplasia,
dysplasia, and squamous cell carcinoma. The staining intensity of PPARα (A), ACC (B), EGFR (C), and COX2 (D) in normal epithelium, squamous hyperplasia, dysplasia, and SCC
increases progressively (Magniﬁcation, 200×). The skeletal muscle derived from murine tongue tissue was used as an internal positive control for the staining quality of these four
antibodies. PPARα, peroxisome proliferator-activated receptor alpha; ACC, acetyl-coenzyme A carboxylase; EGFR, epidermal growth factor receptor; COX2, cyclooxygenase-2.
Fig. 3. Expression of PPARα, ACC, EGFR, and COX2 in the 4-NQO/arecoline-induced oral tumorigenesis mouse model. Ten mice in each group were examined. The
immunohistochemical staining intensity of each protein in the tongue lesions was determined using a scoring system with ﬁve grades from negative (0), weak positive in less than
10% of the area (1), weak positive (2), moderate positive (3), and strong positive immunoreactivity (4). The open bars represent the mean immunoreactivity score of group 6 (0.3%
fenoﬁbrate treatment). The close bars represent the mean immunoreactivity score of group 2 (4-NQO/arecoline only). The error bars represent SD. *pb0.05; **pb0.01.
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when compared with group 2 (Fig. 3A, pb0.05), but no signiﬁcant
difference was found in lesions showing dysplasia or SCC. This ﬁnding
indicated that PPARα activation might play an important role in
hyperplastic lesions. Because PPARα is a key regulator of lipolysis, we
next asked whether the suppression of the tumor incidence and
formation by fenoﬁbrate was not limited to the lipolysis pathway. The
central enzymes in de novo lipogenesis, such as ACC and FAS, were
also examined. The immunoreactivity of ACC was increased with
dietary exposure to fenoﬁbrate in both dysplasia (Fig. 3B, pb0.05) and
hyperplasia (pb0.05) tissues. However, no signiﬁcant differences in
the expression of FAS were found between the 0.3% fenoﬁbrate-
treated and 4-NQO/arecoline only groups (data not shown). These
results indicated that there is another signal between PPARα
activation and tumor progression.
Because EGFR signaling was required for cell survival in the EGFR-
ampliﬁed/overexpressing oral SCC [16] and activation of EGFR
signaling has been reported to drive COX2 transcription [18], we
examined the expressions of EGFR and COX2 after fenoﬁbrate
treatment. We found that administration of 0.3% fenoﬁbrate (group
6) signiﬁcantly increased EGFR expression levels in lesions with
hyperplasia (Fig. 3C, pb0.05) and dysplasia (pb0.05), and signiﬁ-
cantly decreased the expression of EGFR in SCC lesions (pb0.01)when
comparedwith group 2. The immunoreactivity of COX2was increased
with dietary exposure to fenoﬁbrate in dysplasia lesions (Fig. 3D,
pb0.01) and was decreased in SCC lesions (pb0.05). These ﬁndings
indicated that fenoﬁbrate suppressed tumor progression into SCC and
suggested that this might be related to the lower expression levels of
EGFR and COX2 in SCC lesions.
4. Discussion
Activation of PPARα by fenoﬁbrate results in lipid-modifying
actions that inﬂuence atherogenic dyslipidemia [20]. In this study, we
found that the mice treated with the carcinogen 4-NQO/arecoline
(group 2) showed an increase in serum LDL-C and no changes in total
cholesterol and HDL-C levels when compared to control mice (group
1) at the end of 28 weeks. After withdrawal of the carcinogen,
administration of 0.3% fenoﬁbrate for the following 20 weeks
increased serum total cholesterol, LDL-C, and HDL-C levels when
compared to group 2. HDL-C levels were increased in both the 0.1%
and 0.3% fenoﬁbrate feeding groups. PPARα agonists were found to
enhance components of the HDL synthetic pathways and to increase
reverse cholesterol transport [10]. Fenoﬁbrate, a PPARα agonist, was
shown to increase serum HDL-C levels by increasing expression of the
genes for both ApoA-I and ApoA-II, decreasing the cholesteryl ester
transfer protein-mediated transfer of cholesterol from HDL to VLDL.
This transfer enhances the cholesterol efﬂux of the cell by induction of
ATP-binding cassette transporter A1 (ABCA1) expression and de-
creasing scavenger receptor-class B type 1 (SR-B1) in the liver [12,21].
Therefore, the increase in total cholesterol levels in the 0.3%
fenoﬁbrate-treated group might be due to increases in the HDL-C
and LDL-C levels, which were induced by fenoﬁbrate and 4-NQO/
arecoline, respectively. Interestingly, no signiﬁcant differences in
triglyceride levels were observed between the 4-NQO/arecoline only
group and the 4-NQO/arecoline groups treated with fenoﬁbrate.
Administration of fenoﬁbrate did not show the triglyceride lowering
effects on tumor progression after a complete 28-week observation. In
contrast, both 0.1% and 0.3% fenoﬁbrate-treated mice showed a
signiﬁcant increase in triglyceride levels after 20 weeks of treatment
when compared to mice after 12 weeks of treatment. At the end of
28 weeks, we found that 50% of the 0.3% fenoﬁbrate-treated mice
(group 6) were tumor free, 40% had a tumor size less than 2 mm, and
10% had a tumor size of 2 to 4 mm; however, the corresponding
percentages in 0.1% fenoﬁbrate-treatedmice (group 4) were 20%, 20%,
and 60%, respectively. These ﬁndings indicated that the higher levelsof serum triglyceride in the 0.3% fenoﬁbrate-treated mice might be
due to their decreased utilization by neoplastic cells for the
biosynthesis of new membrane as compared with the 0.1% fenoﬁ-
brate-treated mice. The lower rate of tumor incidence and smaller
tumor sizes were evident in the 0.3% fenoﬁbrate-treated mice (Fig. 1).
An inverse association between a lower plasma lipid proﬁle and head
and neck cancer was also found in human studies [6,7].
Long-term (20 weeks) administration of 0.3% fenoﬁbrate reduced
the severity and extent of tongue lesions, which was evident from the
decreased tumor incidence and size as well as the tumor histological
examination. With respect to the incidence of tongue lesions, a 50%
reduction in the 0.3% fenoﬁbrate-treated group was observed when
compared to the 4-NQO/arecoline only group (Fig. 1A). Also, an
average reduction rate of 62.5% was observed in the multiplicity of
SCC (Table 3). However, fenoﬁbrate at a low dose (0.1%/mouse/day)
lacked anti-tumor activity in this study. This result is consistent with
the previous observation that fenoﬁbrate at a low daily dose (0.1%–
0.25%) lacked anti-tumor activity in primary hamster melanoma [22]
andmurine endometrial cancer [23]. Recently, animal studies showed
that activation of PPARα might be attributable to the inhibition of
angiogenesis [24].
Using the 4-NQO/arecoline mouse model, we identiﬁed a tumor
suppressive effect of fenoﬁbrate and suggested that this lipid-
lowering agent might exert some indirect actions on pathways
known to be relevant to oral tumorigenesis. There were two
possibilities that could explain the effect of fenoﬁbrate on tumori-
genesis. First, therewas crosstalk between PPARα activation and EGFR
expression in our study. Fenoﬁbrate increased the EGFR expression
levels in hyperplastic and dysplastic lesions and decreased the EGFR
expression in SCC (Fig. 3C). Notably, EGFR signaling was required for
cell survival in the EGFR-ampliﬁed/overexpression oral SCC [16].
Secondly, fenoﬁbrate-induced COX2 expression was linked to the
development of oral tumorigenesis (Fig. 3D). Previous reports
indicated that activation of the EGFR signaling pathway can drive
COX2 transcription and prostaglandin E2 synthesis, which could
stimulate cell proliferation, induce angiogenesis, inhibit apoptosis,
and suppress immune surveillance [18,25–27]. Moraitis et al. reported
that tobacco smoke stimulated EGFR tyrosine kinase activity leading
to enhanced transcription of COX2 [18]. In our study, 4-NQO, a
surrogate of tobacco exposure, treated concomitantly with arecoline-
induced the expression of EGFR and COX2 in tumor progressive
grades (hyperplasia, dysplasia, and SCC) when compared to normal
tissue. Increases in the expression of EGFR and COX2were observed in
the preneoplastic lesions of fenoﬁbrate-treated mice versus untreated
mice, and, most importantly, there was a decrease in the expression of
EGFR and COX2 in the neoplastic cells. Fenoﬁbrate exhibited a high
potential to inhibit the formation of SCC. Therefore, these results
provide insight into fenoﬁbrate as a suppressor of the progression of
oral tumorigenesis.
In conclusion, the activation of PPARα, which can be linked to the
expression of EGFR and COX2, shows the beneﬁcial effects of fenoﬁbrate
in this oral-speciﬁc 4-NQO/arecoline mouse model. The cascade of
molecular events causes the reduction in the incidence and size of
squamous carcinoma and suppresses the progression of the preneo-
plastic lesion into SCC. Therefore, we suggest that fenoﬁbrate should be
considered as a strategy for preventing oral tumor progression.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2010.11.002.
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